Natural Microalgae-Based Nanocarriers for Drug Delivery, Cosmetics, and Nutraceutics

The project data does not include specific licensing costs or pricing information. As a publicly funded RIA project coordinated by CNR (Italian National Research Council), IP arrangements would need to be negotiated directly with the consortium. Contact through SciTransfer for an introduction to discuss terms.

VES4US developed microfluidic-based production and purification methods specifically designed to overcome the scalability bottleneck of mammalian cell-derived vesicles. The use of microalgae as the source organism is inherently more scalable than human cell cultures. However, the project reached preclinical validation stage, so further scale-up engineering would be needed for commercial volumes.

IP generated under Horizon 2020 RIA projects is typically owned by the consortium partners who created it. The 6-partner consortium across 6 countries (Italy, Germany, Spain, Ireland, Switzerland, Slovenia) would hold different IP components. Specific patent filings and licensing availability should be confirmed directly with the coordinator at CNR.

Based on the deliverable data, preclinical studies in rodents were conducted to assess short-term and long-term systemic toxicity and in vivo stability of microalgae-derived extracellular vesicles. This confirms testing moved beyond lab bench to animal models.

Regulatory classification depends on the end application. For drug delivery, these would fall under pharmaceutical regulations (EMA in Europe, FDA in the US) and require full clinical trials. For cosmetics and nutraceutical applications, the regulatory path is lighter but still requires safety documentation. The preclinical rodent toxicity data from VES4US provides a starting point for regulatory submissions.

The platform produces functionalized vesicles that can be loaded with target molecules — proteins, RNAs, or drug compounds. Based on the project objectives, the vesicles can be tailored for specific tissues including brain, lung, skin, dendritic cells, or tumor cells. Integration would require adapting the microalgae cultivation and vesicle extraction pipeline to your existing formulation workflow.

The consortium includes 1 industrial partner out of 6 total partners (17% industry ratio) and 1 SME. The project objective states it was endorsed by prominent industrial players with interests in market-oriented innovation. However, as a FET-Open project, the primary focus was on breakthrough research rather than near-term commercial deployment.